The UN Standard Minimum Rules for the Treatment of Prisoners (SMRs) were initially adopted by the UN Congress on the Prevention of Crime and the Treatment of Offenders in 1955, and approved by the UN Economic and Social Council in 1957.

On 17 December 2015 a revised version of the Standard Minimum Rules were adopted unanimously by the 70th session of the UN General Assembly. This followed a four-year revision process after a 2010 UN General Assembly resolution which requested revision of the SMRs ‘so that they reflect recent advances in correctional science and best practices’. To find out more about the revision process, please click here.

The revised Rules will be known as the ‘Nelson Mandela Rules‘ to honour the legacy of the late President of South Africa, Mr. Nelson Rolihlahla Mandela, who spent so many years of His life in prison’.

To read Penal Reform International (PRI)'s press release, please click here.

This two-minute animation below explains the Nelson Mandela Rules, what they include, and what they mean for prison management.

Keep up-to-date with drug policy developments by subscribing to the IDPC Monthly Alert.

UN standard minimum rules for the treatment of prisoners - Nelson Mandela Rules

Monitoring of the testing for hepatitis C has been implemented in low-threshold services in Germany, Romania, Portugal and Finland. Low-threshold services were selected as they attract a considerable number of active drug users who might be engaged in risk behaviour. Due to the number of drug users visiting low-threshold services, this setting provides a good opportunity to screen for risk behaviour and the need for HCV testing. Most often lowthreshold services do not monitor the prevalence of infectious diseases among their clients. Therefore the monitoring aimed at collecting data on the proportion of drug users who have been tested for HCV, the prevalence of HCV and the number of drug users that should be tested for hepatitis C.

This report is a product of the European Hepatitis C Initiative. Responsible partner: Centre for Interdisciplinary Addiction Research Centre of Hamburg University, Germany

Monitoring of HCV testing in low-threshold drug services

In a global meeting small scale farmers of cannabis, coca and opium from 14 countries discussed their contribution to the United Nations General Assembly Special Session (UNGASS). The UNGASS will discuss all aspects of global drug control policies, including the worldwide ban on the cultivation of coca, poppy and cannabis, an issue the Global Farmers Forum demands that their voices be heard and taken into account.

The Heemskerk Declaration: Final declaration of the Global Forum of Producers of Prohibited Plants

This open letter outlines extensive scientific evidence that the indicators used to evaluate drug policy ignore some of the most important community impacts. In response, the open letter includes a preliminary set of suggested indicators that allow for governments to better assess the health, security, development and human rights impacts of their drug policies. By reprioritizing the indicators used to evaluate illicit drug policy, governments will be better able to implement targeted and effective policies that align with community needs. The alternative is to continue the unacceptably high levels of drug-related harms, with grave implications for communities across the globe.

 A call for a reprioritisation of metrics to evaluate illicit drug policy

We, representatives of government ministries, law enforcement agencies, drug policy experts and civil society who participated in the Regional Consultation on Drug Policy Reform on “The Road to UNGASS” which was held in Ghana from 19-20 January 2016, which attracted 11 West African countries namely Benin, Burkina Faso, Cabo Verde, Cote D'Ivoire, Ghana, Guinea, Guinea-Bissau, Liberia, Nigeria, Senegal and Sierra Leone hereby make the following declaration with respect to drug policy reform in West Africa;

Reaffirming the Political Declaration and Plan of Action on International Cooperation, the Common African Position towards UNGASS, AU Plan of Action on Drug Control and the ECOWAS Regional Action Plan to address drug trafficking, production and consumption, and calling upon West Africa Member States to take the measures necessary to fully implement the actions set out therein, with the view to attaining, in timely manner their goals and targets.

Acknowledging the serious threat posed by drug trafficking and production to governance, peace and security stability and economic growth in West Africa, a region that has only recently emerged from decades of violent conflict;

Recognising the efforts made by Member States to comply with the provisions of the single Conventions on Narcotic Drug of 1961 as amended by the 1972 Protocol, the Convention on Psychotropic Substances of 1971, and the United Nations Convention against Illicit Traffic in Narcotic Drugs and Psychotropic Substances of 1988;

Acknowledging the threat of drug use to public health and social development in West Africa;

Mindful of the current drug policy that has fostered abuses of human rights of drug users, burdened the criminal justice system, deterioration of public health, proliferation of violence, spread of HIV, hepatitis, tuberculosis prevalence and taking priority away from effective treatment and rehabilitation for people who use drugs;

Acknowledging that narcotic drugs trafficking is a major problem that threatens security, social welfare, economic development and political stability in West Africa;

Welcoming the opportunity that the United Nations General Assembly Special Session (UNGASS) 2016 on the world drug problem provides the region to review its progress in the International Cooperation against the World Drug problem;

Recalling that the world drug problem remains a common and shared responsibility that requires effective and increased international cooperation;

We hereby recommend the following inputs towards the contribution of Member States to the outcome document of the UN General Assembly Special Session.

Keep up-to-date with drug policy developments by subscribing to the IDPC Monthly Alert.

West African common position towards the UNGASS 2016 on the world drug problem

This submission by the International Network of People who Use Drugs (INPUD) to the Civil Society Task Force to UNGASS on Drugs 2016 is derived from INPUD’s Consensus Statement on Drug Use Under Prohibition: Human Rights, Health, and the Law. The INPUD’s Consensus Statement focusses on human rights, health, and the law in relation to people who use drugs. The document – and this submission – is informed by the perspective of those who are so catastrophically impacted by global prohibition and by the so-called ‘war on drugs’: people who use drugs themselves.

This submission stems from five consultations conducted by the INPUD in 2015 with representatives of drug user organisations internationally. Each consultation was comprised of focus groups with participants. Consultations were undertaken in Dar es Salaam, Tanzania, in Bangkok, Thailand, in London, England, and in Tbilisi, Georgia. A virtual consultation was also conducted. In total, representatives of 24 drug user organisations from 28 countries contributed to the consultations.

The assertions made in this submission are driven by the data, reports, and testimony gathered in these consultations; each assertion made in this document is backed up by first-hand testimony from one or several representatives of drug user organisations globally.

INPUD submission to the civil society task force to UNGASS on drugs 2016

Cannabis use has never posed major problems in Indonesia, yet prohibitionist policies prevail. Despite the high prevalence of cannabis use, local or national discussions on cannabis policies are nearly non-existent, exacerbated by strong anti-drug views and public institutions' failure to design and implement comprehensive policies based on evidence.

Cannabis in Indonesia

Public Health England (PHE) have released a free resource to assist prison staff about new psychoactive substances (NPS) in prisons.

The toolkit has been recently released after the HM Inspectorate of Prisons report ‘Changing patterns of substance misuse in adult prisons and service responses’, published in December 2015, which identified NPS as having “created significant additional harm and are now identified as the most serious threat to the safety and security of the prison system.”

The resource is intended to support custodial, healthcare and substance misuse staff by providing information about the extent of NPS use as PHE currently understand it and about the properties of the various categories of NPS, and by providing advice on how to manage the problem from a clinical, psychosocial and regime perspective.

The toolkit also discusses the various challenges that are associated for healthcare staff, such as the covert nature of use, unpredictable effects the various drugs have, the delay in seeking medical help, as well as multiple challenges for the wider prison regime.

New psychoactive substances in prisons: A toolkit for prison staff

Fom October 1-3, 2015 a regional meeting of NGOs, policy makers and scientists/researchers from the countries of Southeast Europe, was organized by Diogenis Association in Belgrade, to discuss the UN General Assembly Special Session on Drugs (UNGASS, April 2016) and its significance for Southeast Europe. The meeting closed with the formulation of some conclusions relevant for the situation in the SEE countries.

The UNGASS 2016 and its significance for SEE: Statement of NGOs in South East Europe

Globalisation has facilitated cultural exchange between indigenous traditions and Western practices, which has led to a growing interest in the ritual, religious and therapeutic use of ayahuasca

Indigenous peoples in the Amazon have used ayahuasca for centuries as a remedy for physical and psychological health, and to ensure the life and wellbeing of their communities. In the past two decades, the use of this decoction has expanded beyond Amazon indigenous spheres. Globalisation, and with it the contact between populations, has facilitated cultural exchange between indigenous traditions and Western practices, which has led to a growing interest in the ritual, religious and therapeutic use of ayahuasca.

People who participate in the sessions have a positive perception of its use; while most scientific research over the past decade supports the subsequent benefits attributed to it. But the increased use of ayahuasca has not been free from challenges, such as its excessive commercialisation in the Amazon, linked to ayahuasca tourism, or the exploitation of natural resources used for its preparation. Despite not being a controlled substance at the international level, and not banned in almost any national jurisdiction, in recent years there have been an extraordinary number of detentions and judicial prosecutions in Europe, the United States and Latin America for ayahuasca importation and use. This contradiction has produced a number of uncertainties regarding its legal and political status, which varies between countries.

In this policy brief, ICEERS and TNI offer an analysis of the challenges associated with the globalisation of ayahuasca.

Ayahuasca: From the Amazon to the global village

The Bridging the Gaps programme aims to increase access to HIV prevention, treatment, care and support and ensure full human rights for key populations, who are most affected by HIV but least supported. The right to lead a healthy and fulfilling life is universal but not accessible for all. In order to improve the access to healthcare services for key populations, the Bridging the Gaps programme aims to integrate specific services for these groups into general healthcare systems, because:

In many countries, key populations which include people living with HIV face social exclusion, discrimination and stigma within the general health system. This negatively affects the access to HIV prevention, treatment, care and support.

Evidence shows that integration of services for key populations increases access to health services.

Providing accessible HIV-related health services for key populations shows a significant reduction in a country’s HIV prevalence.

Integration of services has the potential to be sustainable and cost-efficient for both providers and service users, strengthens health systems and

Lastly, all people have the right to equal access to health services.

Although integration of services is not a new theme, evidence related to implementing and evaluating integration programmes is not readily available. There is little guidance for planners and decision-makers on how to plan and implement integrated health service delivery for key populations. Evidence for low and middle income countries is especially scarce. This document provides lessons learnt of the Bridging the Gaps programme linked to the global strategy of the WHO on integrated and people-centred services for key populations. In 2015 Bridging the Gaps, in collaboration with VU University Amsterdam, conducted qualitative research to collect best practices, lessons learnt and critical facilitators for integrating services in South Africa, Kenya, Uganda, Indonesia, Vietnam and Kyrgyzstan.

Integrated services for key populations: Lessons learnt from the Bridging the Gaps programme

The Scottish National Naloxone Programme has proven to be effective in lowering the number of Opioid-Related Deaths (ORDs) in people recently released from prisons according to a newly published report.

The report entitled ‘Effectiveness of Scotland's National Naloxone Programme for reducing opioid-related deaths: a before (2006-10) versus after (2011-13) comparison’, was published in the Society for the Study of Addiction's journal 'Addiction'.

The study aimed to assess the effectiveness for Scotland’s levels of ORDs between the two time periods, as well as to assess cost-effectiveness of the programme.

The report found that In 2006-2010, 9.8% of ORDs (193 out of 1,970) were in people released from prison within 4 weeks of death, whereas only 6.3% of ORDs in 2011-2013 followed prison release (76 out of 1,212); this represented a reduction of 3.6%.

This reduction in the proportion of prison release ORDs translates into 42 fewer prison release ORDs during 2011-13, when 12,000 naloxone kits were issued at current prescription-cost of £225,000.

In conclusion, the report found that Scotland's National Naloxone Programme, which started in 2011, was associated with a 36% reduction in the proportion of opioid-related deaths that occurred in the 4 weeks following release from prison.

Click here to read the full article (restricted access).

Keep up-to-date with drug policy developments by subscribing to the